Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aging is associated with body composition changes that include a reduction of muscle mass or sarcopenia and an increase in visceral obesity. Thus, aging involves a muscle-fat imbalance with a shift toward more fat and less muscle. Therefore, sarcopenic obesity, defined as a combination of sarcopenia and obesity, is a global health phenomenon due to the increased aging of the population combined with the increased epidemic of obesity. Previous studies have shown inconsistent association between sarcopenic obesity and the risk of cardiovascular disease (CVD). AIMS: To systematically review the recent literature on the CVD risks associated with sarcopenic obesity and summarizes ways of diagnosis and prevention. METHODS: A systematic review of studies that reported the association between sarcopenic obesity and CVD risk in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. RESULTS: Risk factors of sarcopenic obesity included genetic factors, aging, malnutrition, sedentary lifestyle, hormonal deficiencies and other molecular changes. The muscle-fat imbalance with increasing age results in an increase in the pro-inflammatory adipokines secreted by adipocytes and a decline in the anti-inflammatory myokines secreted by myocytes. This imbalance promotes and perpetuates a chronic low-grade inflammatory state that is characteristic of sarcopenic obesity. After application of exclusion criteria, only 12 recent studies were included in this review. The recent studies have shown a consistent association between sarcopenic obesity and cardiovascular disease risk although most of the studies are of cross-sectional design that does not confirm a causal relationship. In addition, most of the population studied were of Asian origin which may limit the generalizability of the results. Non-pharmacological interventions by exercise training and adequate nutrition appear to be useful in maintenance of muscle strength and muscle mass in combination with a reduction of adiposity to promote healthy aging. CONCLUSIONS: Sarcopenic obesity appears to increase the risk of CVD in older people; however, future prospective studies of diverse population are still required. Although non-pharmacologic interventions are useful in reducing the risk of sarcopenic obesity, novel specific pharmacologic agents are lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 1×
“[26,27] The balance between catabolic and anabolic pathways determines muscle metabolic efficiency.”
BackgroundSARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155 · cited 1×
“[69] (Box 2) The diagnosis of sarcopenic obesity should include the diagnosis”
BackgroundAge-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102 · cited 1×
“[34] Similarly, in menopausal women, decreased levels of estrogen results in increased deposition of visceral adipose tissues and decreased fat-free mass.”
Background
Cited by
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
Zhong, F., Xu, Y., Lai, H.-Y., Yang, M., Cheng, L., Liu, X., Sun, X., Yang, Y., Wang, J., Lv, W., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1004863 · Cited by 26
Zhuang, M., Jin, M., Lu, T., Lu, L., Ainsworth, B. E., Liu, Y., & Chen, N. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.917525 · Cited by 18
“At present, there is still a lack of specific pharmacological interventions for SO (Evans et al., 2021).”
BackgroundChen, P., Chang, C., Lin, W., Nagabhushanam, K., Ho, C., & Pan, M. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202101077 · Cited by 8
Metadata
- Authors
- Evans, K., Abdelhafiz, D., & Abdelhafiz, A. H.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2021-07-12
- Volume
- 133
- Issue
- 8
- Pages
- 831-842
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W3168738561
- Cited by
- 61
- References
- 52
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review. https://app.cochat.ai/papers/10.1080/00325481.2021.1942934
- The paper
- Evans, K., Abdelhafiz, D., & Abdelhafiz, A. H. (2021). Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review. Postgraduate Medicine. https://doi.org/10.1080/00325481.2021.1942934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.